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ABSTRACT: A photoactivatable dopamine-conjugated
platinum(IV) anticancer complex (Pt-DA) has been
incorporated into G-quadruplex G4K
+ borate hydrogels
by using borate ester linkages (Pt-G4K
+B hydrogel). These
were characterized by 11B NMR, attenuated total reﬂection
Fourier transform infrared spectroscopy, circular dichro-
ism, scanning electron microscopy and transmission
electron microscopy. Microscopy investigations revealed
the transformation of an extended ﬁber assembly into
discrete ﬂakes after incorporation of Pt-DA. Pt-DA
showed photocytotoxicity against cisplatin-resistant
A2780Cis human ovarian cancer cells (IC50 74 μM, blue
light) with a photocytotoxic index <2, whereas Pt-G4K
+B
hydrogels exhibited more potent photocytotoxicity (IC50 3
μM, blue light) with a photocytotoxic index >5. Most
notably, Pt-DA and Pt-G4K
+B hydrogels show selective
phototoxicity for cancer cells versus normal ﬁbroblast cells
(MRC5).
Although hydrogels are mostly water, they behave like solidsdue to three-dimensional networks of cross-links within
them. Hydrogels often consist of cross-linked polymers and
have the properties of colloidal particles.1 The cross-linking can
be stabilized by many kinds of interactions such as van der Waals
and covalent interactions, and hydrogen bonding.2 There is
increasing interest in designing hydrogels made from bio-
molecules with potential applications in biology, medicine and
materials science. Stimuli-responsive hydrogels are particularly
attractive in the ﬁeld of drug delivery and tissue engineering.3
Guanosine monophosphate (5′-GMP) and other derivatives of
guanosine have been known to form gels for decades.4
Guanosine-based hydrogels are stabilized by stacking of G-
quartets on top of one another to form extended helices.
Recently, Davis et al. designed G4K
+ borate hydrogels and
studied the role of the anion and cation in the stability of the
gels.5 They noted that when the guanosine analogue acyclovir,
an antiviral drug, is incorporated in to the G4K
+ borate hydrogel,
the release of acyclovir is facilitated by the slow self-destruction
of the hydrogel. This strategy can be successfully applied to
provide slow and sustained release of acyclovir from G4K
+
borate hydrogels.6
Flexibility and high water content of hydrogels allow them to
mimic natural tissues, thereby paving the way for the
development of hydrogel-based delivery systems particularly
for topical medication. Recently, injectable hydrogels have been
shown to have potential as delivery vehicles for cancer therapy.7
Photochemotherapy for cancer has the potential to provide
spatial and temporal control of drug activity in tumors with
fewer side-eﬀects on normal cells, as well as novel mechanisms
of action which combat resistance. The anticancer activity of
diazido-Pt(IV) complexes is mainly due to photoreduction of
inert Pt(IV) to cytotoxic Pt(II) together with release of reactive
azidyl radicals.8 Small molecule cancer drugs often suﬀer from
systemic toxicity and lack of selective uptake by cancer cells. The
incorporation of photoactive platinum-based anticancer drugs in
hydrogels limits drug exposure and facilitates slow release of the
drug speciﬁcally at the target site, triggered by light irradiation.
Here we use biocompatible G4K
+ hydrogels to deliver a
photoactivatable a platinum(IV) prodrug to cancer cells. This
strategy might allow treatment of surface cancers such as
esophagus, lung, skin and bladder using spatially directed
irradiation with minimal damage to normal tissues. To achieve
this goal, we have synthesized a photoactivatable diazido-Pt(IV)
complex appended with dopamine, a neurotransmitter as well as
a constituent of adhesive proteins in mussels. Dopamine and
polydopamines possess self-assembly properties, extensively
used as anchors for attachment of functional molecules on
diﬀerent substrates.9 Moreover, the antiangiogenesis properties
of dopamine have been explored by Basu et al.10 We prepared a
dopamine-conjugated photoactivatable Pt(IV) complex (Pt-
DA) in order to conjugate it to a G4K
+ borate hydrogel using
catechol-borate and guanosine-borate interactions. The syn-
thesis of Pt-DA involved reacting dopamine hydrochloride with
trans,trans,trans-[Pt(N3)2(Py)2(OH)(succinate)] using amide
coupling (Scheme S1). The photoactivation and decomposition
of Pt-DA were investigated by irradiation with 420 nm blue light
in 1:1 (v/v) methanol:water. The photoreaction was followed
by UV−vis and 1H NMR spectroscopy. The change in the UV−
vis spectrum was monitored every 5 min for 1 h. Figure 2A
shows the gradual reduction in intensity of the N3→ Pt LMCT
band at ca. 300 nm corresponding to electron transfer from
azide to Pt(IV) and formation of Pt(II). To understand the
reduction process, 1H NMR spectra of Pt-DA in the dark were
recorded as well as after irradiation at 420 nm for 2 h. The 1H
NMR spectrum showed the presence of both Pt(II) and Pt(IV)
species (Figure 2B). The UV−vis spectrum showed the
formation of a broad band around 420−600 nm after irradiation,
Received: January 6, 2017
Published: April 17, 2017
Communication
pubs.acs.org/JACS
© 2017 American Chemical Society 5656 DOI: 10.1021/jacs.7b00186
J. Am. Chem. Soc. 2017, 139, 5656−5659
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
indicating slow oxidation of dopamine to the quinone. Pt-
G4K
+B hydrogel was prepared in a one-pot reaction by treating
Pt-DA with boric acid and potassium hydroxide in water for 30
min, followed by the addition of guanosine hydrate, under
constant stirring for 2 h at 343 K (Scheme S2). The reaction
mixture was then allowed to cool to ambient temperature
overnight aﬀording a brown-colored gel (Figure 1 inset).
To investigate how Pt-DA is attached to G4K
+ borate
hydrogel, we treated Pt-DA with boric acid and potassium
hydroxide (without guanosine hydrate) yielding Pt-DA-borate
ester (Pt-DA-B). Pt-DA is sparingly soluble in water, but after
mono borate ester formation the solubility improved. A color
change from yellow to dark brown was observed within a few
minutes, indicating formation of the monoborate ester. The
progress of the reaction was monitored by UV−vis spectrosco-
py, which showed the appearance of a weak band at ca. 400−550
nm corresponding to monoborate ester, similar to that reported
by Kim et al. during catechol-borate gel formation.11 1H NMR
showed the disappearance of catechol −OH resonances at 8.62
and 8.73 ppm after mono borate ester formation. This was
further conﬁrmed by electrospray ionisation mass spectrometry
(ESI-MS, Figure S3). This observation clearly indicated that the
brown color of the gel is due to the incorporation of Pt-DA-
Borate ester, whereas G4K
+ borate hydrogel is colorless. The
mol ratio of Pt-DA relative to guanosine hydrate is crucial for gel
formation, when 1 mol equiv of Pt-DA was used, no gel
formation was observed. The presence of the Pt-DA functional
group on the four arms of the G-quartet may cause steric
disruption to the stacking of G-quartets. Reducing the molar
ratio of Pt-DA to 0.1 mol equiv resulted in gel formation.
The Pt-G4K
+B hydrogel was characterized by attenuated total
reﬂection Fourier transform infrared spectroscopy (ATR-FTIR)
and 11B NMR. ATR-FTIR spectra of Pt-G4K
+B hydrogel, G4K
+
borate hydrogel, guanosine and boric acid are shown in Figure
2D together with selected peak assignments. The amide
vibration (ν(CO), δ(NH2)) of free guanosine at 1726 cm
−1
Figure 1. Schematic representation of the self-assembly of Pt-DA
functionalized G4K
+ borate hydrogels. (Inset shows synthesized Pt-
G4K
+B hydrogel.)
Figure 2. (A) UV−vis spectra of Pt-DA before and after irradiation with 420 nm blue light, scans were recorded every 5 min for 1 h in 1:1 v/v water:
methanol. (B) 1H NMR spectra of Pt-DA before and after irradiation at 420 nm in DMSO-d6 (assignments: a, b, c correspond to Pt-py peaks, green
colored stars correspond to Pt(II) photoproduct). (C) 11 B NMR spectra of boric acid, borate, Pt-DA-Borate and Pt-G4K
+B hydrogel in D2O. (D)
ATR-FTIR spectra of (a−d) guanosine hydrate, G4K+ borate hydrogel, Pt-G4K+B hydrogel and boric acid, respectively.
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decreases in wavenumbers when guanosine amide is involved in
H-bonding networks. As expected, the amide vibrations of Pt-
G4K
+B hydrogel, and G4K
+ borate hydrogel appear at 1697
cm−1. The observed decrease between guanosine and the gels
(29 cm−1) is due to intermolecular H-bonding between
guanosines.12 Pt-G4K
+B hydrogel shows the νasym(N3) at 2050
cm−1, conﬁrming the presence of Pt-DA (Figure S4). Boric acid
(Figure 2Dd) gives rise to two δ(B−OH) vibrations at 1000 and
1191 cm−1, and a broad ν(B−O) vibration at 1407 cm−1. ATR-
FTIR spectra of Pt-G4K
+B hydrogel and G4K
+ borate hydrogel
show a broad feature for ν(B−O), whereas ν(B−OH) vibrations
were not observed indicating the formation of borate diesters.
Borate monoester and diester formation in D2O were studied by
11B NMR spectroscopy (Figure 2C). Boric acid shows a signal at
18.5 ppm, whereas borate displays a peak at 1.87 ppm. When Pt-
DA was added, the latter signal shifted to 2.73 ppm indicating
the formation of Pt-DA-monoborate ester (Pt-DA-B). Guano-
sine hydrate was then added to the solution, which was heated
to 343 K for 2 h. The 11B NMR spectrum showed two peaks at
4.25 and 8.05 ppm.
The peak at 4.25 ppm corresponds to borate diester of Pt-DA
and guanosine (Pt-DA-B-G) and the peak at 8.05 ppm to
guanosine borate diester (G-B-G).
The Pt-G4K
+B hydrogel was also characterized by micros-
copy. Scanning electron microscopy (SEM) images of the Pt-
G4K
+B gel in water show ﬂake-like assemblies (Figure 3C).
Further the Energy Dispersive X-ray (EDX) spectrum of Pt-
G4K
+B gel conﬁrmed the presence of C, O, N, B, K and Pt in the
ﬂakes (Figure 3F). As a control, the self-assembly of G4K
+
borate hydrogel was studied under similar conditions as those
for Pt-G4K
+B gel. G4K
+ borate hydrogel forms an extensive ﬁber
assembly due to stacking of G-quartets in helices (Figure 3B), an
observation which matches well with a recent report.5a
Transmission electron microscopy (TEM) images also show
ﬂake-like assembly (Figure 3D). We also performed raster
scanning transmission electron microscopy (STEM) for better
spatial resolution. STEM images indicate the presence of pores
in the ﬂakes (Figure 3E), suggesting that incorporation of Pt-
DA has a signiﬁcant role in the transformation of extensive ﬁbril
assembly into discrete ﬂakes.
We recorded circular dichroism (CD) spectra to characterize
changes in conformation that might accompany changes in the
assembly process (Figure S5). The CD spectrum of G4K
+ borate
hydrogel shows two positive peaks at 254 and 295 nm and a
negative peak at 234 nm. This CD spectrum conﬁrms the
formation of G4 quartet stacking in the G4K
+ borate hydrogel.5a
Stacking occurs in both head-to-head and head-to-tail fashion.
After addition of Pt-DA, signiﬁcant changes were observed in
the CD spectrum of Pt-G4K
+B gel. This observation supports
the conclusion that incorporating Pt-DA aﬀects the conforma-
tion and hence the assembly process.
The anticancer activity of Pt-DA and Pt-G4K
+B hydrogel was
determined in the dark as well as under blue light irradition, by
using the sulforhodamine B (SRB) colorimetric assay. IC50
values were determined for cisplatin-resistant A2780Cis human
ovarian cancer cells (Figure 4) and the noncancerous human
ﬁbroblast cell line MRC-5. Both cell lines were treated with Pt-
DA and Pt-G4K
+B hydrogel for 1 h in the dark, followed by
irradiating one set of plates for 1 h using blue LEDs (465 nm, 50
mW), whereas the other was kept in a dark incubator. After
Figure 3. (A) Schematic representation of incorporation of Pt-DA into
G4K
+ borate hydrogel. (B and C) SEM images of G4K
+ borate hydrogel
and Pt-G4K
+B hydrogel. (D) TEM image of Pt-G4K
+B hydrogel. (E)
STEM image shows the presence of pores in the ﬂake assembly. (F)
EDX of Pt-G4K
+B hydrogel showing the elemental composition (K, Pt,
C, N and O) of the ﬂakes.
Figure 4. Growth curves for A2780Cis cells treated for 1 h with (A) Pt-
DA and (B) Pt-G4K
+B hydrogel, followed by 1 h irradiation with blue
LEDs (465 nm, 50 mW). Cells were allowed to recover for 24 h in
drug-free medium before determination of viability.
Table 1. IC50 (μM) Values for Pt-DA and Pt-G4K
+ Borate
Hydrogel against Cisplatin-Resistant A2780Cis Human
Ovarian Cancer Cells and normal MRC-5 Human Fibroblast
Cells, in Comparison with Chlorpromazine (CPZ) and
Cisplatin (CDDP)a
IC50 (μM)
A2780Cis MRC5
compound dark blue (465 nm) dark blue (465 nm)
Pt-G4K
+B gel 15.8 ± 0.6 2.8 ± 0.3 >50 >50
Pt-DA 138.03 ± 0.09 74.1 ± 0.2 >200 >150
CPZ 51.2 ± 0.4 6.3 ± 0.2 >100 >50
CDDP >100 >100 >100 >100
aCDDP is nontoxic under the short treatment conditions used here (1
h drug exposure). IC50 values for Pt-DA, Pt-G4K
+ and CDDP
(concentration for 50% cell growth inhibition), based on Pt
concentrations by ICP-OES.
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irradiation, the cells were allowed to recover over 24 h and
compared with untreated cells that were irradiated under similar
conditions. These experiments also compared irradiated versus
nonirradiated untreated cells in order to conﬁrm that the
observed cell death was not the result of light exposure. The
diﬀerence between these two cell populations was in no case
statistically signiﬁcant. Pt-DA was relatively nontoxic toward
A2780Cis cells in the dark (IC50 138 μM, Table 1), but upon
irradiation with blue light it exhibited moderate antiproliferative
activity (IC50 74 μM, photocytoxicity index (PI) 1.9). In
contrast, Pt-G4K
+B hydrogel displayed activity against
A2780Cis in the dark (IC50 = 16 μM), and was highly potent
upon irradiation (IC50 = 3 μM, Table 1) with a higher
photocytotoxicity index (PI) of 5.6. Hence, both the photo-
cytotoxicity and PI of Pt-DA increase signiﬁcantly after
incorporation into the G4K
+ borate gel. We further investigated
the survival of A2780Cis cells exposed to a mixture of (a) Pt-DA
with borate in a molar ratio 1:6, and (b) Pt-DA with borate and
guanosine in a molar ratio of 1:6:10. Remarkably, there were no
statistical diﬀerences in survival of cells treated only with Pt-DA
and those treated with mixtures a or b. Thus, neither borate nor
guanosine increase the toxicity of Pt-DA per se, and hence the
increase in potency of Pt-G4K
+B compared to Pt-DA is related
to the gel and the delivery (Figures S6 and S7). Our experiments
also included controls in which A2780Cis cells were treated only
with either borate (up to 1.5 mM) or guanosine (up to 2.5 mM),
or a combination of both. In all three cases, the percentages of
cell survival were not statistically diﬀerent from those of
untreated A2780Cis cells. To study their cell selectivity, we
tested them against MRC-5 normal lung ﬁbroblasts. Under the
same experimental conditions, both Pt-DA and Pt-G4K
+B
hydrogel were nontoxic toward normal cells (IC50 > 50 μM)
giving a photocytotoxicity selectivity factor (ratio of the activity
between normal and cancer cells), of >18 for the Pt-G4K
+B
hydrogel.
In conclusion, we have used a new strategy to design
hydrogels that can deliver photoactivatable Pt(IV) anticancer
complexes to cancer cells. We conjugated a photoactive Pt(IV)
complex to G4K
+B hydrogel using borate ester formation. This
modiﬁcation transformed the self-assembled G4K
+B hydrogel
from extended ﬁbers into discrete ﬂakes. Incorporation of Pt-
DA into the G4K
+B hydrogel dramatically increased its
photocytotoxic potency toward cisplatin-resistant human
ovarian cancer cells. Most importantly, the chemical mod-
iﬁcation dramatically increased the selectivity between normal
and cancer cells (>18-fold) which is an early indication of the
possibility of reducing unwanted side eﬀects by the use of the
hydrogel as a delivery strategy. Such high potency and selectivity
provides a strong basis for development of this new class of
materials as photochemotherapeutic agents, with potential for
localized immunogenic treatment of cancers.13
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